The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) approved a phase 1 clinical trial to confirm ABX464’s pharmacokinetic profile in Japanese subjects

This phase 1 study is required to include Japan in Abivax’s ABX464 global phase 3 program for the treatment of ulcerative colitis

As part of Abivax’s ABX464 late-stage development plan, three additional phase 1 studies are being conducted in healthy volunteers, all progressing according to plan

Abivax plans to initiate its global phase 3 clinical program in UC by year end

Following the announcement of the ABX464 phase 2b top-line data in UC, the full results will be communicated during the first half of September